Anaesthetic-related neuroprotection: Intravenous or inhalational agents?

CNS Drugs

Volumn 24, Issue 11, 2010, Pages 893-907

  Schifilliti, Daniela ^a   Grasso, Giovanni ^b   Conti, Alfredo ^a   Fodale, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

anaesthesia; anaesthetics, pharmacodynamics; barbiturates, pharmacodynamics; desflurane, pharmacodynamics; halothane, pharmacodynamics; isoflurane, pharmacodynamics; ketamine, pharmacodynamics; neuroprotection; nitrous oxide, pharmacokinetics; pentobarbital, pharmacodynamics; phenobarbital, pharmacodynamics; propofol, pharmacodynamics; sevoflurane, pharmacodynamics; thiopental sodium, pharmacodynamics; xenon, pharmacodynamics

Indexed keywords

ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; DESFLURANE; HALOTHANE; ISOFLURANE; KETAMINE; MIDAZOLAM; NITROUS OXIDE; PENTOBARBITAL; PHENOBARBITAL; PROPOFOL; SEVOFLURANE; THIOPENTAL; VOLATILE AGENT; XENON;

ANESTHESIA; ANGER; ANOREXIA; APOPTOSIS; BRAIN INJURY; BRAIN TISSUE; CINAHL; COCHRANE LIBRARY; DATA BASE; DEGENERATION; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; INFLAMMATION; MEDICAL LITERATURE; MEDLINE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PUBLISHING; REVIEW; SIDE EFFECT; SLEEP DISORDER; STROKE;

ADMINISTRATION, INHALATION; ANESTHESIA, INTRAVENOUS; ANESTHETICS; ANIMALS; BRAIN INJURIES; BRAIN ISCHEMIA; CARDIOPULMONARY BYPASS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; CRANIOTOMY; HUMANS; INHALATION; NEUROPROTECTIVE AGENTS; RATS; TIME FACTORS;

EID: 77957836723     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11584760-000000000-00000     Document Type: Review

References (132)

1. Sreedhar R, Gadhinglajkar SV. Pharmacological neuroprotection. Indian J Anaesth 2003; 47: 8-22
2. Mortier L, Struys M, Herregods L. Therapeutic coma or neuroprotection by anaesthetics. Acta Neurol Belg 2000; 100: 225-8
3. Toner CC, Stanford LA. General anaesthetics as neuroprotective agents. Baillieres Clini Anesthesiol 1996; 10: 515-33
4. Miura Y, Amagasa S. Perioperative cerebral ischemia and the possibility of neuroprotection by inhalational anesthetics [in Japanese]. Masui 2003; 52: 116-27
5. Matchett GA, Allard MW, Martin RD, et al. Neuroprotective effect of volatile anesthetic agents: molecular mechanisms. Neurol Res 2009; 31: 128-34
6. Brasil LJ, San-Miguel B, Kretzmann NA, et al. Halothane induces oxidative stress and NF-kB activation in rat liver: protective effect of propofol. Toxicology 2006; 227: 53-61
7. Nakao S, Nagata A, Masuzawa M, et al. NMDA receptor antagonist neurotoxicity and psychotomimetic activity [in Japanese]. Masui 2003; 52: 594-602
8. Haelewyn B, Yvon A, Hanouz JL, et al. Desflurane affords greater protection than halothane against focal cerebral ischaemia in the rat. Br J Anaesth 2003; 91: 390-6
9. Kobayashi M, Takeda Y, Taninishi H, et al. Quantitative evaluation of the neuroprotective effects of thiopental sodium, propofol, and halothane on brain ischemia in the gerbil: effects of the anesthetics on ischemic depolarization and extracellular glutamate concentration. J Neuro-surg Anesthesiol 2007; 19: 171-8
10. Wang C, Jin Lee J, Jung HH, et al. Pretreatment with volatile anesthetics, but not with the nonimmobilizer 1,2-dichlorohexafluorocyclobutane, reduced cell injury in rat cerebellar slices after an in vitro simulated ischemia. Brain Res 2007; 1152: 201-8
11. Wise-Faberowski L, Raizada MK, Sumners C. Oxygen and glucose deprivation-induced neuronal apoptosis is attenuated by halothane and isoflurane. Anesth Analg 2001; 93: 1281-7
12. Istaphanous GK, Loepke AW. General anesthetics and the developing brain. Curr Opin Anaesthesiol 2009; 22: 368-73
13. Loepke AW, Soriano SG. An assessment of the effects of general anesthetics on developing brain structure and neu-rocognitive function. Anesth Analg 2008; 106: 1681-707
14. Kain ZN, Caldwell-Andrews AA, Weinberg ME. Sevoflurane versus halothane: postoperative maladaptive behavioral changes: a randomized, controlled trial. An-esthesiology 2005; 102: 720-6
15. Keaney A, Diviney D, Harte S, et al. Postoperative behavioral changes following anesthesia with sevoflurane. Paediatric Anaesth 2004; 14: 866-70
16. Kotiniemi LH, Ryhanen PT, Moilanen IK. Behavioural changes in children following day-case surgery: a 4-week follow-up of 551 children. Anaesthesia 1997; 52: 970-6
17. Modvig KM, Nielsen SF. Psychological changes in children after anaesthesia: a comparison between halothane and ketamine. Acta Anaesthesiol Scand 1977; 21: 541-4
18. Uemura E, Levin ED, Bowman RE. Effects of halothane on synaptogenesis and learning behavior in rats. Exp Neurol 1985; 89: 520-9
19. Smith RF, Bowman RE, Katz J. Behavioral effects of exposure to halothane during early development in the rat: sensitive period during pregnancy. Anesthesiology 1978; 49: 319-23
20. Zheng S, Zuo Z. Isoflurane preconditioning reduces purkinje cell death in an in vitro model of rat cerebellar ischemia. Neuroscience 2003; 118: 99-106
21. Zheng S, Zuo Z. Isoflurane preconditioning decreases glutamate receptor overactivation-induced Purkinje neuronal injury in rat cerebellar slices. Brain Res 2005; 1054: 143-51
22. Zhao P, Peng L, Li L, et al. Isoflurane preconditioning improves long-term neurologic outcome after hypoxic-ischemic brain injury in neonatal rats. Anesthesiology 2007; 107: 963-70
23. Wei H, Liang G, Yang H. Isoflurane preconditioning inhibited isoflurane-induced neurotoxicity. Neurosci Lett 2007; 425: 59-62
24. Li QF, Zhu YS, Jiang H. Isoflurane preconditioning activates HIF-1alpha, iNOS and Erk1/2 and protects against oxygen-glucose deprivation neuronal injury. Brain Res 2008; 1245: 26-35
25. Xiong L, Zheng Y, Wu M, et al. Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate- regulated potassium channels after focal cerebral ischemia in rats. Anesth Analg 2003; 96: 233-7
26. Lee JJ, Li L, Jung HH, et al. Postconditioning with isoflurane reduced ischemia-induced brain injury in rats. Anesthesiology 2008; 108: 1055-62
27. Engelhard K, Werner C, Reeker W, et al. Desflurane and isoflurane improve neurological outcome after incomplete cerebral ischaemia in rats. Br J Anaesth 1999; 83: 415-21
28. Inoue S, Davis DP, Drummond JC, et al. The combination of isoflurane and caspase 8 inhibition results in sustained neuroprotection in rats subject to focal cerebral ischemia. Anesth Analg 2006; 102: 1548-55
29. Wang L, Kitano H, Hurn PD, et al. Estradiol attenuates neuroprotective benefits of isoflurane preconditioning in ischemic mouse brain. J Cereb Blood Flow Metab 2008; 28: 1824-34
30. Sasaoka N, Kawaguchi M, Kawaraguchi Y, et al. Isoflurane exerts a short-term but not a long-term preconditioning effect in neonatal rats exposed to a hypoxic-ischaemic neuronal injury. Anaesthesiol Scand 2009; 53: 46-54
31. Brambrink AM, Evers AS, Avidan MS, et al. Isoflurane induced neuroapoptosis in the neonatal rhesus macaque brain. Anesthesiology 2010; 112: 834-41
32. Ma D, Williamson P, Januszewski A, et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology 2007; 106: 746-53
33. Lu LX, Yon JH, Carter LB, et al. General anesthesia activates BDNF-dependent neuroapoptosis in the developing rat brain. Apoptosis 2006; 11: 1603-15
34. Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing brain and persistent learning deficits. J Neurosci 2003; 23: 876-82
35. Lunardi N, Ori C, Erisir A, et al. General anesthesia causes long-lasting disturbances in the ultrastructural properties of developing synapses in young rats. Neurotox Res 2010; 17: 179-88
36. Stratmann G, Sall JW, May LD, et al. Beyond anesthetic properties: the effects of isoflurane on brain cell death, neurogenesis, and long-term neurocognitive function. Anesth Analg 2010; 110: 431-7
37. Stratmann G, Sall JW, May LD, et al. Isoflurane differentially affects neurogenesis and long-term neurocogni-tive function in 60-day-old and 7-day-old rats. Anesthe-siology 2009; 110: 834-48
38. Johnson SA, Young C, Olney JW. Isoflurane-induced neuroapoptosis in the developing brain of nonhypoglycemic mice. J Neurosurg Anesthesiol 2008; 20: 21-8
39. Bedforth NM, Girling KJ, Skinner HJ, et al. Effects of desflurane on cerebral autoregulation. Br J Anaesth 2007; 87: 193-7
40. Boisson-Bertrand D, Laxenaire MC, Mertes PM. Recovery after prolonged anaesthesia for acoustic neuroma surgery: desflurane versus isoflurane. Anaesth Intensive Care 2006; 34: 338-42
41. Wise-Faberowski L, Raizada MK, Sumners C. Desflurane and sevoflurane attenuate oxygen and glucose deprivation-induced neuronal cell death. J Neurosurg Anesthe-siol 2003; 15: 193-9
42. Erdem AF, Cesur M, Alici HA, et al. Effects of sevoflurane and desflurane in CA1 after incomplete cerebral ischemia in rats. Saudi Med J 2005; 26: 1424-8
43. Loepke AW, Priestley MA, Schultz SE, et al. Desflurane improves neurologic outcome after low-flow cardiopulmonary bypass in newborn pigs. Anesthesiology 2002; 97: 1521-7
44. Hoffman WE, Charbel FT, Edelman G, et al. Thiopental and desflurane treatment for brain protection. Neuro-surgery 1998; 43: 1050-3
45. Wang ZP, Zhang ZH, Zeng YM, et al. Protective effect of sevoflurane preconditioning on oxygen-glucose deprivation injury in rat hippocampal slices: the role of mitochondrial K(ATP) channels. Sheng Li Xue Bao 2006; 58: 201-6
46. Luo Y, Ma D, Ieong E, et al. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology 2008; 109: 782-9
47. Payne RS, Akca O, Roewer N, et al. Sevoflurane-induced preconditioning protects against cerebral ischemic neuronal damage in rats. Brain Res 2005; 1034: 147-52
48. Ye Z, Guo Q, Wang E, et al. Sevoflurane preconditioning induced delayed neuroprotection against focal cerebral ischemia in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34: 152-7
49. Canas PT, Velly LJ, Labrande CN, et al. Sevoflurane protects rat mixed cerebrocortical neuronal-glial cell cultures against transient oxygen-glucose deprivation: involvement of glutamate uptake and reactive oxygen species. Anesthesiology 2006; 105: 990-8
50. Bercker S, Bert B, Bittigau P, et al. Neurodegeneration in newborn rats following propofol and sevoflurane anesthesia. Neurotox Res 2009; 16: 140-7
51. Berns M, Zacharias R, Seeberg L, et al. Effects of sevoflurane on primary neuronal cultures of embryonic rats. Eur J Anaesthesiol 2009; 26: 597-602
52. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature 1994; 367: 607-14
53. Sanders RD, Ma D, Maze M. Xenon: elemental anaesthesia in clinical practice. Br Med Bull 2005; 71: 115-35
54. Gruss M, Bushell TJ, Bright DP, et al. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 2004; 65: 443-52
55. Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels: comparison with isoflurane and ethanol. Anesthesiology 2000; 93: 1095-101
56. David HN, Ansseau M, Lemaire M, et al. Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization. Biol Psychiatry 2006; 60: 49-57
57. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998; 4: 460-3
58. Haelewyn B, David HN, Rouillon C, et al. Neuroprotection by nitrous oxide: facts and evidence. Crit Care Med 2008; 36: 2651-9
59. Abraini JH, David HN, Lemaire M. Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Ann NY Acad Sci 2005; 1053: 289-300
60. Abraini JH, David HN, Nicole O, et al. Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration. Anesthesiology 2004; 101: 260-1
61. David HN, Leveille F, Chazalviel L, et al. Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab 2003; 23: 1168-73
62. Abraini JH, David HN, MacKenzie ET, et al. Postischemic nitrous oxide alone versus intraischemic nitrous oxide in the presence of isoflurane: what it may change for neuroprotection against cerebral stroke in the rat [letter]. Anesth Analg 2005; 101: 614
63. Eishima K. The effects of obstetric conditions on neonatal behaviour in Japanese infants. Early Hum Dev 1992; 28: 253-63
64. Hollmen AI, Jouppila R, Koivisto M, et al. Neurologic activity of infants following anesthesia for cesarean section. Anesthesiology 1978; 48: 350-6
65. David HN, Haelewyn B, Risso JJ, et al. Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2010; 30: 718-28
66. Remsen LG, Pagel MA, McCormick CI, et al. The influence of anaesthetic choice, PaCO2, and other factors on osmotic blood-brain disruption in rats with brain tumor xenografts. Anesth Analg 1999; 88: 559-67
67. Johansson BB, Linder LE. Cerebrovascular permeability to protein in the rat during nitrous oxide anaesthesia at various blood pressure levels. Acta Anaesthesiol Scand 1978; 22: 463-6
68. David HN, Haelewyn B, Rouillon C, et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J 2008; 22: 1275-86
69. Ma D, Wilhelm S, Maze M, et al. Neuroprotective and neurotoxic properties of the 'inert' gas, xenon. Br J An-aesth 2002; 89: 739-46
70. Sanders RD, Maze M. Xenon: from stranger to guardian. Curr Opin Anaesthesiol 2005; 18: 405-11
71. Wilhelm S, Ma D, Maze M, et al. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiol-ogy 2002; 96: 1485-91
72. Dinse A, Fohr KJ, Georgieff M, et al. Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones. Br J Anaesth 2005; 94: 479-85
73. Ma D, Yang H, Lynch J, et al. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocogni-tive dysfunction in the rat. Anesthesiology 2003; 98: 690-8
74. Schmidt M, Marx T, Gloggl E, et al. Xenon attenuates cerebral damage after ischemia in pigs. Anesthesiology 2005; 102: 929-36
75. Clark JA, Ma D, Homi HM, et al. Xenon and the inflammatory response to cardiopulmonary bypass in the rat. J Cardiothorac Vasc Anesth 2005; 19: 488-93
76. Fries M, Nolte KW, Coburn M, et al. Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med 2008; 36: 2420-6
77. Homi HM, Yokoo N, Ma D, et al. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 2003; 99: 876-81
78. Dingley J, Tooley J, Porter H, et al. Xenon provides shortterm neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006; 37: 501-6
79. Ma D, Hossain M, Pettet GK, et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab 2006; 26: 199-208
80. Coburn M, Maze M, Franks NP. The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med 2008; 36: 588-95
81. David HN, Haelewyn B, Chazalviel L, et al. Post-ischemic helium provides neuroprotection in rats subjected to middle cerebral artery occlusion-induced ischemia by producing hypothermia. J Cereb Blood Flow Metab 2009; 29: 1159-65
82. Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol 2005; 58: 182-93
83. Hobbs C, Thoresen M, Tucker A, et al. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hy-poxia/ischemia. Stroke 2008; 39: 1307-13
84. Thoresen M, Hobbs CE, Wood T, et al. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab 2009; 29: 707-14
85. Cattano D, Williamson P, Fukui K, et al. Potential of xenon to induce or to protect against neuroapoptosis in the developing mouse brain. Can J Anaesth 2008; 55: 429-36
86. Kawaguchi M, Furuya H, Patel PM. Neuroprotective effects of anesthetic agents. J Anesth 2005; 19: 150-6
87. Mantz J. Neuroprotective effects of anesthetics. Ann Fr Anesth Reanim 1999; 18: 588-92
88. Bleyaert A, Sands PA, Nemoto EM, et al. Experimental study of barbiturate application following anoxic en-cephalopathy. Ann Anesthesiol Fr 1978; 19: 827-31
89. Brain Resuscitation Clinical Trial I Study Group. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. N Engl J Med 1986; 314: 397-403
90. Safar P. Cerebral resuscitation after cardiac arrest: a review. Circulation 1986; 74: IV138-53
91. Kirsch JR, Traystman RJ, Hurn PD. Anesthetics and cerebroprotection: experimental aspects. Int Anesthesiol Clin 1996; 34 (4): 73-93
92. Schmid-Elsaesser R, Schroder M, Zausinger S, et al. EEG burst suppression is not necessary for maximum barbiturate protection in transient focal cerebral ischemia in the rat. J Neurol Sci 1999; 162: 14-9
93. Adachi N. Brain protection by anesthetics [in Japanese]. Masui 2006; 55: 542-51
94. Narimatsu E, Niiya T, Kawamata M, et al. The mechanisms of depression by benzodiazepines, barbiturates and propofol of excitatory synaptic transmissions mediated by adenosine neuromodulation [in Japanese]. Masui 2006; 55: 684-91
95. Ohtsuka T, Ishiwa D, Kamiya Y, et al. Effects of barbiturates on ATP-sensitive K channels in rat substantia nigra. Neuroscience 2006; 137: 573-81
96. Perez-Barcena J, Llompart-Pou JA, Homar J, et al. Pentobarbital versus thiopental in the treatment of refractory intracranial hypertension in patients with traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12: R112
97. Brown-Croyts LM, Caton PW, Radecki DT, et al. Phenobarbital pre-treatment prevents kainic acid-induced impairments in acquisition learning. Life Sci 2000; 67: 643-50
98. Varathan S, Shibuta S, Shimizu T, et al. Hypothermia and thiopentone sodium: individual and combined neuropro-tective effects on cortical cultures exposed to prolonged hypoxic episodes. J Neurosci Res 2002; 68: 352-62
99. Asimiadou S, Bittigau P, Felderhoff-Mueser U, et al. Protection with estradiol in developmental models of apop-totic neurodegeneration. Ann Neurol 2005; 58: 266-76
100. Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA 2002; 99: 15089-94
101. Guo J, White JA, Batjer HH. The protective effects of thiopental on brain stem ischemia. Neurosurgery 1995; 37: 490-5
102. Zarchin N, Guggenheimer-Furman E, Meilin S, et al. Thiopental induced cerebral protection during ischemia in gerbils. Brain Res 1998; 780: 230-6
103. Xue QS, Yu BW, Wang ZJ, et al. Effects of ketamine, midazolam, thiopental, and propofol on brain ischemia injury in rat cerebral cortical slices. Acta Pharmacol Sin 2004; 25: 115-20
104. Chen L, Gong Q, Xiao C. Effects of propofol, midazolam and thiopental sodium on outcome and amino acids accumulation in focal cerebral ischemia-reperfusion in rats. Chin Med J (Engl) 2003; 116: 292-6
105. Jevtovic-Todorovic V, Wozniak DF, Powell S, et al. Propofol and sodium thiopental protect against MK-801-induced neuronal necrosis in the posterior cingula-te/retrosplenial cortex. Brain Res 2001; 913: 185-9
106. Dahmani S, Tesniere A, Rouelle D, et al. Thiopental and isoflurane attenuate the decrease in hippocampal phosphorylated focal adhesion kinase (pp125FAK) content induced by oxygen-glucose deprivation. Br J Anaesth 2004; 93: 270-4
107. Shibuta S, Varathan S, Mashimo T. Ketamine and thiopental sodium: individual and combined neuroprotective effects on cortical cultures exposed to NMDA or nitric oxide. Br J Anaesth 2006; 97: 517-24
108. Fredriksson A, Ponten E, Gordh T, et al. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits. Anesthesiology 2007; 107: 427-36
109. Adombri C, Venturi L, Tani A, et al. Neuroprotective effects of propofol in models of cerebral ischemia: inhibition of mitochondrial swelling as a possible mechanism. An-esthesiology 2006; 104: 80-9
110. Kotani Y, Shimazawa M, Yoshimura S, et al. The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther 2008; 14: 95-106
111. Ito H, Watanabe Y, Isshiki A, et al. Neuroprotective properties of propofol and midazolam, but not pento-barbital, on neuronal damage induced by forebrain ischemia, based on the GABAA receptors. Acta Anaes-thesiol Scand 1999; 43: 153-62
112. Grasshoff C, Gillessen T. Effects of propofol on N-methyl-D-aspartate receptor-mediated calcium increase in cultured rat cerebrocortical neurons. Eur J Anaesthesiol 2005; 22: 467-70
113. Velly LJ, Guillet BA, Masmejean FM, et al. Neuroprotective effects of propofol in a model of ischemic cortical cell cultures: role of glutamate and its transporters. Anesthe-siology 2003; 99: 368-75
114. Kotani Y, Nakajima Y, Hasegawa T, et al. Propofol exerts greater neuroprotection with disodium edetate than without it. J Cereb Blood Flow Metab 2008; 28: 354-66
115. Adombri C, Venturi L, Pellegrini-Giampietro DE. Neuroprotective effects of propofol in acute cerebral injury. CNS Drug Rev 2007; 13: 333-51
116. Cattano D, Young C, Straiko MM, et al. Subanesthetic doses of propofol induce neuroapoptosis in the infant mouse brain. Anesth Analg 2008; 106: 1712-4
117. Pesic V, Milanovic D, Tanic N, et al. Potential mechanism of cell death in the developing rat brain induced by propofol anesthesia. Int J Dev Neurosci 2009; 27: 279-87
118. Pfenninger E, Himmelseher S. Neuroprotection by ketamine at the cellular level. Anaesthesist 1997; 46 Suppl. 1: S47-54
119. Rovnaghi CR, Garg S, Hall RW, et al. Ketamine analgesia for inflammatory pain in neonatal rats: a factorial randomized trial examining long-term effects. Behav Brain Funct 2008; 4: 35
120. Sakai T, Ichiyama T, Whitten CW, et al. Ketamine suppresses endotoxin-induced NF-kappaB expression. Can J Anaesth 2000; 47: 1019-24
121. Wang L, Jing W, Hang YN. Glutamate-induced c-Jun expression in neuronal PC12 cells: the effects of ketamine and propofol. Neurosurg Anesthesiol 2008; 20: 124-30
122. Lips J, de Haan P, Bodewits P, et al. Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. Anesthesiology 2000; 93: 1303-11
123. Zou X, Patterson TA, Divine RL, et al. Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int J Dev Neurosci 2009; 27: 727-31
124. Zou X, Patterson TA, Sadovova N, et al. Potential neurotoxicity of ketamine in the developing rat brain. Toxicol Sci 2009; 108: 149-58
125. Soriano SG, Liu Q, Li J, et al. Ketamine activates cell cycle signaling and apoptosis in the neonatal rat brain. Anesthesiology 2010; 112: 1155-63
126. Hans P, Bonhomme V. Why we still use intravenous drugs as the basic regimen for neurosurgical anaesthesia. Curr Opin Anaesthesiol 2006; 19: 498-503
127. Kanbak M, Saricaoglu F, Avci A, et al. Propofol offers no advantage over isoflurane anesthesia for cerebral protection during cardiopulmonary bypass: a preliminary study of S-100beta protein levels. Can J Anaesth 2004; 51: 712-7
128. Statler KD, Alexander H, Vagni V, et al. Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats. J Neurotrauma 2006; 23: 97-108
129. Engelhard K, Werner C. Inhalational or intravenous anesthetics for craniotomies? Pro inhalational. Curr Opin Anaesthesiol 2006; 19: 504-8
130. Koerner IP, Brambrink AM. Brain protection by anesthetic agents. Curr Opin Anaesthesiol 2006; 19: 481-6
131. Head BP, Patel P. Anesthetics and brain protection. Curr Opin Anaesthesiol 2007; 20: 395-9
132. Turner BK, Wakim JH, Secrest J, et al. Neuroprotective effects of thiopental, propofol, and etomidate. AANA J 2005; 73: 297-302